

05-05-2004

002



102738418

# RECOMMENDATION FORM COVER SHEET PATENTS ONLY

 U.S. Department of Commerce  
 Patent and Trademark Office  
**PATENT**

TO: The Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy(ies).

**Submission Type**

- ☒ New  
☐ Resubmission (Non-Recordation)  
 Document ID #  
☐ Correction of PTO Error  
 Reel #                      Frame #  
☐ Corrective Document  
 Reel #                      Frame #

**Conveyance Type**

- ☒ Assignment  
☐ License  
☐ Merger  
☐ Security Agreement  
☐ Change of Name  
☐ Other:

**Conveying Party(ies)****Execution Date(s)**

1. Akira NAKAGAWARA

20 November 2003

☐ Mark if Additional Names of Conveying Parties Attached
**Receiving Parties (2)**

Name Hisamitsu Pharmaceutical Co., Inc.  
 Address 408, Tashirodaikan-machi, Tosu-shi, Saga 841-0017, JAPAN

Name Chiba-Prefecture  
 Address 1-1, Ichiba-cho, Chuo-ku, Chiba-shi, Chiba 280-8667, JAPAN

☐ Mark if Additional Names of Receiving Parties Attached

**Correspondent Name and Address**  
 (202) 419-7000

Fitch, Even, Tabin & Flannery  
 1801 K Street, N.W., Suite 401L  
 Washington, D.C. 20006-1201

Telephone: (202) 419-7000  
 Facsimile: (202) 419-7007  
 Attorney Docket No. 7388/80899

**Pages 1** Enter the total number of pages of the attached conveyance document including any attachments: 1
**Application Number(s) or Patent Number(s)**
☐ Mark if additional numbers attached

Enter either the Patent Application Number or the Patent Number (DO NOT ENTER BOTH numbers for the same property).

Patent Application Numbers			Patent Numbers		
10/478,914					

If this document is being filed together with a new Patent Application, enter the date the patent application was signed by the first named executing inventor.

Month Day Year

**Patent Cooperation Treaty (PCT)**
 Enter PCT application number *only if* a U.S. Application Number has not been assigned.

PCT	PCT	PCT
PCT	PCT	PCT

**Number of Properties**

Enter the total number of properties involved: 1

**Fee Amount**

Fee Amount for Properties Listed (37 CFR 3.41):

**Method of Payment:**

- ☐ Enclosed is a check in the amount of \$40.00  
☒ Charge Deposit Account No. 06-1135 the amount of \$40.00, under Order No. 7388/80899.  
 Authorization to Charge Additional Fees to Deposit Account No. 06-1135: ☒ Yes ☐ No

**Statement and Signature**

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Charges to deposit account are authorized, as indicated herein.

Kendrew H. Colton, 30,368  
 Name of Person Signing

Signature

April 27, 2004  
 Date

05/04/2004 DBYRNE 00000169 061135 10478914  
 01 FC:8021 40.00 DA

PAGE 2/3 \*RCVD AT 4/27/2004 3:49:20 PM [Eastern Daylight Time] \* SVR:USPTO-EFXXF-1/1 \* DNIS:8729306 \* CSID:202 419 7007 \* DURATION (mm:ss):01:18

PATENT  
 REEL: 015283 FRAME: 0329

For Non-U.S. Clients

**ASSIGNMENT**

Whereas, I/we,

NameAddress

c/o Chiba Cancer Center Research Institute,

1) Akira NAKAGAWARA

665-2, Nitona-cho,  
Chuo-ku, Chiba-shi, Chiba 260-0801 Japanhereinafter called assignor(s), have invented certain improvements in  
**NUCLEIC ACIDS ISOLATED IN HUMAN NEUROBLASTOMA**and executed an application for Letters Patent of the United States of America therefor on even date herewith unless  
otherwise indicated below:

filed on \_\_\_\_\_ Serial No. \_\_\_\_\_; and

Whereas

**HISAMITSU PHARMACEUTICAL CO., INC.**408, Teshirodaikan-machi,  
Tosu-shi, Saga 841-0017 Japan

and, Chiba-Prefecture

1-1, Ichiba-cho,  
Chuo-ku, Chiba-shi, Chiba 260-8667 Japan(assignee), desires to acquire the entire right, title and interest in the application and invention, and to any United States  
patents to be obtained therefor;

NOW THEREFORE, be it known that, for good and valuable consideration from assignee, the receipt of which is hereby acknowledged, I/WE, as assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the assignee, its lawful successors and assigns, MY/OUR entire right, title, and interest in and to this invention and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues thereof, and I/WE hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue all Letters Patent for this invention to assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY further covenant and agree that I/WE will, without further consideration, communicate with assignee, its successors and assigns, any facts known to ME/US respecting this invention and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver all papers that may be necessary or desirable to perfect the title to this invention in said assignee, its successors and assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States, it being understood that any expense incident to the execution of such papers shall be borne by the assignee, its successors and assigns.

INVENTORSDATE SIGNED1):  
Name:  
AKIRA NAKAGAWARA

Nov. 20, 2003

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. § 261)

Page 1 of 1

PAGE 3/3 \* RCVD AT 4/27/2004 3:49:20 PM [Eastern Daylight Time] \* SVR:USPTO-EFXXF-1/1 \* DNIS:8729306 \* CSID:202 419 7007 \* DURATION (mm-ss):01-18

RECORDED: 04/27/2004

PATENT  
REEL: 015283 FRAME: 0330